Skip to main content

Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA.

Publication ,  Journal Article
Morgan, TO; McLeod, DG; Leifer, ES; Moul, JW; Murphy, GP
Published in: Prostate Suppl
1996

BACKGROUND: Prostate-specific antigen (PSA) is a most valuable tool for the early detection of prostate cancer; however, it has a high false-positive rate as presently used in prostate cancer screening programs. Patients with persistent PSA elevations, normal digital rectal examinations, and multiple negative biopsies present a clinical dilemma. We prospectively evaluated whether free PSA improves the specificity of PSA and can be useful as a clinical guide to avoid repeat prostate biopsies in a group of such patients. METHODS: Sixty-seven men with persistent PSA elevations (mean 9.6 ng/mL; range 4.1-24.8 ng/mL), normal digital rectal examinations, and two or more prior sextant biopsies (mean 2.8), had serum collected for measurement of total and free PSA. All patients were rebiopsied to determine the receiver-operating characteristics (ROC) of total PSA vs. percent free PSA for prostate cancer detection. RESULTS: This study by biopsy identified 11 new prostate cancer cases. The median percent free PSA was significantly higher at 18.1% among men without prostate cancer, compared to 6.4% in men with prostate cancer (P < 0.00005). When sensitivity was plotted against I-specificity, the area under the receiver-operating curve (ROC) for percent free PSA was 0.95, compared to 0.75 for free PSA density, 0.59 for PSA density, and 0.54 for PSA. In patients with elevated total PSA levels, normal digital rectal examinations, and two prior sets of negative sextant prostate biopsies, a cutoff of 10% free PSA would maintain sensitivity at 91% with a corresponding specificity of 86%. CONCLUSIONS: Selective measurement of percent free PSA in cases of uncertain diagnosis can significantly improve the specificity of prostate cancer detection compared to total PSA alone. A low percent free PSA (< 10%) appears to be a significant predictor of prostate cancer even after two or more negative prostate biopsies.

Duke Scholars

Published In

Prostate Suppl

ISSN

1050-5881

Publication Date

1996

Volume

7

Start / End Page

58 / 63

Location

United States

Related Subject Headings

  • Reoperation
  • ROC Curve
  • Prostate-Specific Antigen
  • Prostate
  • Prospective Studies
  • Middle Aged
  • Male
  • Humans
  • Biopsy
  • Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morgan, T. O., McLeod, D. G., Leifer, E. S., Moul, J. W., & Murphy, G. P. (1996). Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. Prostate Suppl, 7, 58–63.
Morgan, T. O., D. G. McLeod, E. S. Leifer, J. W. Moul, and G. P. Murphy. “Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA.Prostate Suppl 7 (1996): 58–63.
Morgan TO, McLeod DG, Leifer ES, Moul JW, Murphy GP. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. Prostate Suppl. 1996;7:58–63.
Morgan, T. O., et al. “Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA.Prostate Suppl, vol. 7, 1996, pp. 58–63.
Morgan TO, McLeod DG, Leifer ES, Moul JW, Murphy GP. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. Prostate Suppl. 1996;7:58–63.

Published In

Prostate Suppl

ISSN

1050-5881

Publication Date

1996

Volume

7

Start / End Page

58 / 63

Location

United States

Related Subject Headings

  • Reoperation
  • ROC Curve
  • Prostate-Specific Antigen
  • Prostate
  • Prospective Studies
  • Middle Aged
  • Male
  • Humans
  • Biopsy
  • Aged